Concepedia

Laura Aschenbrenner

LA

10

Publications

779

Citations

10

H-Index

2001

Active since

Affiliations

Pfizer (United States)(Current)

Covance (United States)

Nexogen (United States)

Allogene Therapeutics (United States)

Bristol-Myers Squibb (Germany)

Laura Aschenbrenner is an author at Pfizer (United States) specializing in molecular biology, pathogenesis, and immunology.

Top concepts

Publications per year

2001–2019

10

Publications

10

Sialidase Fusion Protein as a Novel Broad-Spectrum Inhibitor of Influenza Virus Infection

Michael P. Malakhov, Laura Aschenbrenner, Donald F. Smee et al. · Antimicrobial Agents and Chemotherapy · 2006 · 231 citations · Full text

DAS181, A Novel Sialidase Fusion Protein, Protects Mice from Lethal Avian Influenza H5N1 Virus Infection

Jessica A. Belser, Xiuhua Lu, Kristy J. Szretter et al. · The Journal of Infectious Diseases · 2007 · 140 citations

, , +14

RN927C, a Site-Specific Trop-2 Antibody–Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models

Pavel Strop, Thomas-Toan Tran, Magdalena Dorywalska et al. · Molecular Cancer Therapeutics · 2016 · 98 citations

Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer

Guoyun Zhu, Davide Foletti, Xiaohui Liu et al. · Scientific Reports · 2019 · 70 citations · Full text

DAS181, a sialidase fusion protein, protects human airway epithelium against influenza virus infection: an in vitro pharmacodynamic analysis

Gallen Triana‐Baltzer, Maria Babizki, Michael C. W. Chan et al. · Journal of Antimicrobial Chemotherapy · 2009 · 64 citations · Full text

Rows per page

1–5 of 10